1. Cytotoxic
1.1. DNA target
1.1.1. Damage
1.1.1.1. Alkylating agents (CCNS) N7 to N7
1.1.1.1.1. Nitrogen mustards
1.1.1.1.2. Nitrosureas
1.1.1.1.3. Alkylsulfonates
1.1.1.2. Methylating agents O6-cytocine
1.1.1.2.1. metabolically activated
1.1.1.3. Platinating agents N7 of guanine to adenine - intrastrand
1.1.1.3.1. Cisplatin
1.1.1.3.2. Carboplatin
1.1.1.3.3. Oxaliplatin
1.1.1.4. Free radical forming Antibiotic
1.1.1.4.1. Bleomycin (G2 phase)
1.1.2. Inhibit synth. or transcr.
1.1.2.1. Antimetabolites (S phase)
1.1.2.1.1. Folic acid analogs
1.1.2.1.2. Pyrimidine analogs
1.1.2.1.3. Purine analogs
1.1.2.2. Topo inh. (S phase)
1.1.2.2.1. Camptothecins - topo1
1.1.2.2.2. Anthracyclines (-rubicin) CCNS
1.1.2.2.3. Etoposide (VP-16)
1.1.2.2.4. Dactinomycin (actinomycin-D) CCNS
1.1.2.3. Hydroxyurea (PO) (S phase)
1.1.2.3.1. iron chelator, scavenges free rad. inhibiting ribonucleotide reductase
1.1.2.3.2. desquamative interstitial pneumonitis, skin toxicity
1.1.2.3.3. induces HbF prod in bone marrow - less sickle cells
1.2. Miscellaneous
1.2.1. Asparaginase
1.2.1.1. sequence of admin imp. - starves lymphoid cells
1.2.1.2. pancreatitis, immunosupp, hyperglycemia
1.2.2. Lenolinamide
1.2.2.1. immunomod, antiangiogenic, antitumor
1.2.2.2. peripheral sensory neuropathy
1.2.3. Retinoids
1.2.3.1. displaces repressor - allows for differentiation of cells
1.2.3.2. retinoic acid syndrome - weight gain, pulm inf. pericardial eff.
1.3. Mitotic spindle inhibitors
1.3.1. vinca alkaloids (metaphase) - binds a-tubulin (+) inh. polymerization
1.3.1.1. Vincristine
1.3.1.1.1. no myelosup.
1.3.1.2. Vinblastine
1.3.1.2.1. myelosupp.
1.3.2. taxanes (prophase) - binds b-subunit (-) preventing depolymerization
1.3.2.1. myelosupp. IV need surfactant - infusion run.
2. Targeted
2.1. Antibodies
2.1.1. VEGF
2.1.1.1. Pulmonary hemorrhage, GI perforation
2.1.1.1.1. Bevacizumab
2.1.1.1.2. Ramucirumab
2.1.2. HER2
2.1.2.1. Cardiomyopathy
2.1.2.1.1. Trastuzumab
2.1.2.1.2. Pertuzumab
2.1.3. EGFR
2.1.3.1. Skin rash
2.1.3.1.1. Cetuximab
2.1.3.1.2. Panitumumab
2.1.4. CD20
2.1.4.1. B cell depletion
2.1.4.1.1. Rituximab
2.1.4.1.2. Ofatumumab
2.2. Immunomodulators
2.2.1. Severe T-cell med. dermatitis
2.2.1.1. Effector T upreg. (anti-PD-1)
2.2.1.1.1. Nivolumab
2.2.1.1.2. Pembrolizumab
2.2.1.2. Naive T cell upreg. (anti-CTLA-4)
2.2.1.2.1. Ipilumumab
2.2.2. IL2 rec. agonist
2.2.2.1. contrain. w/ serious organ dz.
2.2.3. IFNa 2b
2.2.3.1. autoimmune, depression, infection
2.2.4. ex vivo stim. T cells with PAP
2.2.4.1. Sipuleucel-T
2.3. Tyrosine Kinase Inhibitors
2.3.1. BCR-ABL and c-kit
2.3.1.1. Dasatinib
2.3.1.2. Imatinib
2.3.1.3. Nilotinib
2.3.2. VEGFR
2.3.2.1. peripheral neuropathy
2.3.2.1.1. Pazopanib
2.3.2.1.2. Sunitinib
2.3.2.1.3. Sofafenib
2.3.3. HER2
2.3.3.1. Lapatinib
2.3.4. EGFR
2.3.4.1. derm. tox.
2.3.4.1.1. Erlotinib
2.3.4.1.2. Gefitinib
2.3.4.1.3. Lapatinib
2.3.5. BRAF (V600E)
2.3.5.1. Dabrafenib
2.3.5.1.1. Cardiomyopathy
2.3.5.2. Vemurafenib
2.3.6. ALK
2.3.6.1. Crizotinib
2.4. Miscellaneous
2.4.1. Hedgehog signaling
2.4.1.1. basal cell carcinoma
2.4.1.2. inhibit SMO
2.4.1.2.1. Teratogen
2.4.2. mTOR inhibitors
2.4.2.1. Sirolimus, Evrolimus, Temsirolimus
2.4.3. Proteosome inhibitors > more IkB, less NfkB
2.4.3.1. Bortezomib, Carfilzomib, Ixazomib
2.4.3.1.1. peripheral neuropathy, acute CHF
2.4.4. HDAC inhibitors
2.4.4.1. Panobinostat
2.4.5. CDK4/6
2.4.5.1. Palbociclib
2.4.5.1.1. reduce ER+/Her2- breast prolif.